Stock comparison
Eli Lilly
Masimo
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$946.37B
Sector
Healthcare
MASI
Masimo
Market cap
$9.35B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | MASI | Winner |
|---|---|---|---|
| Warren Buffett | 65B | 39D | LLY |
| Benjamin Graham | 76B | 66B | LLY |
| Philip Fisher | 75B | 40D | LLY |
| Peter Lynch | 64C | 26F | LLY |
| Joel Greenblatt | 68B | 53C | LLY |
| Charlie Munger | 75B | 42D | LLY |
| Terry Smith | 66B | 33F | LLY |
Side-by-side metrics
| Metric | LLY | MASI |
|---|---|---|
| Market cap | $946.37B | $9.35B |
| P/E (TTM) | 35.6x | 122.1x |
| EV/EBIT | 33.2x | 31.0x |
| ROIC (TTM) | 32.06% | 18.28% |
| Gross margin | 83.51% | 61.73% |
| Net margin | 34.98% | 4.9% |
| Revenue CAGR 5y | 23.17% | 5.36% |
| EPS CAGR 5y | 40.81% | - |
| Debt / Equity | 1.4x | 0.6x |
| Dividend yield | 0.64% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Dividend yield0.64%vs 0.0%+100%
- Market cap$946.37Bvs $9.35B+99%
- Net margin34.98%vs 4.9%+86%
- Revenue CAGR 5y23.17%vs 5.36%+77%
MASI leads on
- Debt / Equity0.6xvs 1.4x+56%
- EV/EBIT31.0xvs 33.2x+6%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.